Suppression of Pseudomonas aeruginosa quorum-sensing systems by macrolides: A promising strategy or an oriental mystery?

Journal of Infection and Chemotherapy

Volumn 13, Issue 6, 2007, Pages 357-367

  Tateda, Kazuhiro ^a   Ishii, Yoshikazu ^a   Kimura, Soichiro ^a   Horikawa, Manabu ^b   Miyairi, Shinichi ^c   Yamaguchi, Keizo ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SUNTORY INSTITUTE FOR BIOORGANIC RESEARCH   (Japan)

^c NIHON UNIVERSITY   (Japan)

Author keywords

Autoinducer; Cystic fibrosis; Diffuse panbronchiolitis; Macrolide; Pseudomonas aeruginosa; Quorum sensing system

Indexed keywords

AZITHROMYCIN; CEFTAZIDIME; CLARITHROMYCIN; ELASTASE; ERYTHROMYCIN; EXOPOLYSACCHARIDE; JOSAMYCIN; KITASAMYCIN; LEUKOCIDIN; MACROLIDE; MINOCYCLINE; OFLOXACIN; PIGMENT; PLACEBO; PROTEINASE; ROKITAMYCIN; ROXITHROMYCIN; TOBRAMYCIN; TOXIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; BACTERIAL CELL; BACTERIAL INFECTION; BACTERIAL PROTEIN SYNTHESIS; BACTERIAL VIRULENCE; CELL ADHESION; CELL SURFACE; CYSTIC FIBROSIS; DIFFUSE PANBRONCHIOLITIS; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG PROTEIN BINDING; GROWTH INHIBITION; HOST CELL; HUMAN; LUNG INFECTION; MINIMUM INHIBITORY CONCENTRATION; PATHOGENESIS; PROTEIN SYNTHESIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS AERUGINOSA INFECTION; QUORUM SENSING; REVIEW;

ANTI-BACTERIAL AGENTS; BRONCHIOLITIS; CYSTIC FIBROSIS; HUMANS; MACROLIDES; PSEUDOMONAS AERUGINOSA; QUORUM SENSING;

EID: 37349067977     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-007-0555-2     Document Type: Review

References (87)

1. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999;27:887-92.
2. Hoiby N. Diffuse panbronchiolitis and cystic fibrosis: East meets West. Thorax 1994;49:531-2.
3. Wilson R, Dowling RB. Lung infections. 3. Pseudomonas aeruginosa and other related species. Thorax 1998;53:213-9.
4. Passador L, Cook JM, Gambello MJ, Rust L, Iglewski BH. Expression of Pseudomonas aeruginosa virulence genes requires cell-to-cell communication. Science 1993;260:1127-30.
5. Kaplan HB, Greenberg EP. Diffusion of autoinducer is involved in regulation of the Vibrio fischeri luminescence system. J Bacteriol 1985;163:1210-4.
6. Pearson JP, Gray KM, Passador L, Tucker KD, Eberhard A, Iglewski BH, et al. Structure of the autoinducer required for expression of Pseudomonas aeruginosa virulence genes. Proc Natl Acad Sci USA 1994;91:197-201.
7. Pearson JP, Passador L, Iglewski BH, Greenberg EP. A second N-acylhomoserine lactone signal produced by Pseudomonas aeruginosa. Proc Natl Acad Sci USA 1995;92:1490-4.
8. Kudoh S, Uetake T, Hagiwara K, Hirayama M, Hus LH, Kimura H, et al. Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis (in Japanese). Nihon Kyobu Shikkan Gakkai Zasshi 1987;25:632-42.
9. Tateda K, Standiford TJ, Pechere JC, Yamaguchi K. Regulatory effects of macrolides on bacterial virulence: potential role as quorum-sensing inhibitors. Curr Pharm Des 2004;10:3055-65.
10. Tateda K, Ishii Y, Yamaguchi K. Quorum-sensing system of Pseudomonas aeruginosa - a novel target for antibacterial agents (in Japanese). Nippon Saikingaku Zasshi 2004;59:543-9.
11. Butts JD. Intracellular concentrations of antibacterial agents and related clinical implications. Clin Pharmacokinet 1994;27:63-84.
12. Tulkens PM. Intracellular distribution and activity of antibiotics. Eur J Clin Microbiol Infect Dis 1991;10:100-6.
13. Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989;33:277-82.
14. Tateda K, Ishii Y, Matsumoto T, Furuya N, Nagashima M, Matsunaga T, et al. Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. Antimicrob Agents Chemother 1996;40:2271-5.
15. Gemmell CG. Antibiotics and neutrophil function-potential immunomodulating activities. J Antimicrob Chemother 1993;3 1(Suppl B):23-33.
16. McDonald PJ, Pruul H. Macrolides and the immune system. Scand J Infect Dis Suppl 1992;83:34-40.
17. Homma H, Yamanaka A, Tanimoto S, Tamura M, Chijimatsu Y, Kira S, et al. Diffuse panbronchiolitis. A disease of the transitional zone of the lung. Chest 1983;83:63-9.
18. Izumi T. Japanese clinical statistical data of patients with diffuse panbronchiolitis (in Japanese). Nippon Rinsho 1992; 50 Suppl: 386-94.
19. Izumi T. Diffuse panbronchiolitis. Chest 1991;100:596-7.
20. Fitzgerald JE, King TE, Jr, Lynch DA, Tuder RM, Schwarz MI. Diffuse panbronchiolitis in the United States. Am J Respir Crit Care Med 1996;154:497-503.
21. Sugiyama Y, Kudoh S, Maeda H, Suzaki H, Takaku F. Analysis of HLA antigens in patients with diffuse panbronchiolitis. Am Rev Respir Dis 1990;141:1459-62.
22. Takeda H, Miura H, Kawahira M, Kobayashi H, Otomo S, Nakaike S. Long-term administration study on TE-031 (A-56268) in the treatment of diffuse panbronchiolitis (in Japanese). Kansenshogaku Zasshi 1989;63:71-8.
23. Ashitani J, Doutsu Y, Ii T, Taniguchi H, Matsukura S. A case of diffuse panbronchiolitis relieved rapidly by the treatment of roxithromycin (in Japanese). Kansenshogaku Zasshi 1992;66:657-8.
24. Kobayashi H, Takeda H, Sakayori S, Kawakami Y, Otsuka Y, Tamura M, et al. Study on azithromycin in treatment of diffuse panbronchiolitis (in Japanese). Kansenshogaku Zasshi 1995;69:711-22.
25. Yamamoto M, Kondo A, Tamura M, Izumi T, Ina Y, Noda M. Long-term therapeutic effects of erythromycin and new quinolone antibacterial agents on diffuse panbronchiolitis (in Japanese). Nihon Kyobu Shikkan Gakkai Zasshi 1990;28:1305-13.
26. Nagai H, Shishido H, Yoneda R, Yamaguchi E, Tamura A, Kurashima A. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration 1991;58:145-9.
27. Fujii T, Kadota J, Kawakami K, Iida K, Shirai R, Kaseda M, et al. Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection. Thorax 1995;50:1246-252.
28. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 1998;157:1829-32.
29. Jaffe A, Francis J, Rosenthal M, Bush A. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 1998;351:420.
30. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002;57:212-6.
31. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002;360:978-84.
32. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290:1749-56.
33. Pollack M. The virulence of Pseudomonas aeruginosa. Rev Infect Dis 1984;6(Suppl 3):S617-26.
34. Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 1996;60:539-74.
35. Yasuda H, Ajiki Y, Koga T, Kawada H, Yokota T. Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin. Antimicrob Agents Chemother 1993;37:1749-55.
36. Ichimiya T, Yamasaki T, Nasu M. In-vitro effects of antimicrobial agents on Pseudomonas aeruginosa biofilm formation. J Antimicrob Chemother 1994;34:331-41.
37. Ichimiya T, Takeoka K, Hiramatsu K, Hirai K, Yamasaki T, Nasu M. The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro. Chemotherapy 1996;42:186-91.
38. Kobayashi H. Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides. Am J Med 1995;99:26S-30S.
39. Ripoll L, Reinert P, Pepin LF, Lagrange PH. Interaction of macrolides with alpha dornase during DNA hydrolysis. J Antimicrob Chemother 1996;37:987-91.
40. Kita E, Sawaki M, Oku D, Hamuro A, Mikasa K, Konishi M, et al. Suppression of virulence factors of Pseudomonas aeruginosa by erythromycin. J Antimicrob Chemother 1991;27:273-84.
41. Molinari G, Paglia P, Schito GC. Inhibition of motility of Pseudomonas aeruginosa and Proteus mirabilis by subinhibitory concentrations of azithromycin. Eur J Clin Microbiol Infect Dis 1992;11:469-71.
42. Molinari G, Guzman CA, Pesce A, Schito GC. Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. J Antimicrob Chemother 1993;31:681-8.
43. Hirakata Y, Kaku M, Mizukane R, Ishida K, Furuya N, Matsumoto T, et al. Potential effects of erythromycin on host defense systems and virulence of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1992;36:1922-7.
44. Mizukane R, Hirakata Y, Kaku M, Ishii Y, Furuya N, Ishida K, et al. Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1994;38:528-33.
45. Sakata K, Yajima H, Tanaka K, Sakamoto Y, Yamamoto K, Yoshida A, et al. Erythromycin inhibits the production of elastase by Pseudomonas aeruginosa without affecting its proliferation in vitro. Am Rev Respir Dis 1993;148:1061-5.
46. Sato K, Suga M, Nishimura J, Kushima Y, Muranaka H, Ando M. Pyocyanine synthesis by Pseudomonas aeruginosa in chronic airway infection and the effect of erythromycin on its biological activity (in Japanese). Jpn J Antibiot 1997;50(Suppl):89-91.
47. Menninger JR, Coleman RA, Tsai LN. Erythromycin, lincosamides, peptidyl-tRNA dissociation, and ribosome editing. Mol Gen Genet 1994;243:225-33.
48. Tateda K, Ishii Y, Hirakata Y, Matsumoto T, Ohno A, Yamaguchi K. Profiles of outer membrane proteins and lipopolysaccharide of Pseudomonas aeruginosa grown in the presence of sub-MICs of macrolide antibiotics and their relation to enhanced serum sensitivity. J Antimicrob Chemother 1994;34:931-42.
49. Tateda K, Hirakata Y, Furuya N, Ohno A, Yamaguchi K. Effects of sub-MICs of erythromycin and other macrolide antibiotics on serum sensitivity of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1993;37:675-80.
50. Shibl AM. Effect of antibiotics on adherence of microorganisms to epithelial cell surfaces. Rev Infect Dis 1985;7:51-65.
51. Yamasaki T, Ichimiya T, Hirai K, Hiramatsu K, Nasu M. Effect of antimicrobial agents on the piliation of Pseudomonas aeruginosa and adherence to mouse tracheal epithelium. J Chemother 1997;9:32-7.
52. Kawamura-Sato K, Iinuma Y, Hasegawa T, Horii T, Yamashino T, Ohta M. Effect of subinhibitory concentrations of macrolides on expression of flagellin in Pseudomonas aeruginosa and Proteus mirabilis. Antimicrob Agents Chemother 2000;44:2869-72.
53. Saiman L, Chen Y, Gabriel PS, Knirsch C. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 2002;46:1105-7.
54. Bui KQ, Banevicius MA, Nightingale CH, Quintiliani R, Nicolau DP. In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa. J Antimicrob Chemother 2000;45:57-62.
55. Yanagihara K, Tomono K, Sawai T, Kuroki M, Kaneko Y, Ohno H, et al. Combination therapy for chronic Pseudomonas aeruginosa respiratory infection associated with biofilm formation. J Antimicrob Chemother 2000;46:69-72.
56. Tateda K, Ishii Y, Matsumoto T, Kobayashi T, Miyazaki S, Yamaguchi K. Potential of macrolide antibiotics to inhibit protein synthesis of Pseudomonas aeruginosa: suppression of virulence factors and stress response. J Infect Chemother 2000;6:1-7.
57. Lam J, Chan R, Lam K, Costerton JW. Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis. Infect Immun 1980;28:546-56.
58. Gilligan PH. Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev 1991;4:35-51.
59. Gambello MJ, Iglewski BH. Cloning and characterization of the Pseudomonas aeruginosa lasR gene, a transcriptional activator of elastase expression. J Bacteriol 1991;173:3000-9.
60. Ochsner UA, Koch AK, Fiechter A, Reiser J. Isolation and characterization of a regulatory gene affecting rhamnolipid biosurfactant synthesis in Pseudomonas aeruginosa. J Bacteriol 1994;176:2044-54.
61. Glessner A, Smith RS, Iglewski BH, Robinson JB. Roles of Pseudomonas aeruginosa las and rhl quorum-sensing systems in control of twitching motility. J Bacteriol 1999;181:1623-9.
62. Rumbaugh KP, Griswold JA, Iglewski BH, Hamood AN. Contribution of quorum sensing to the virulence of Pseudomonas aeruginosa in burn wound infections. Infect Immun 1999;67:5854-62.
63. Pearson JP, Feldman M, Iglewski BH, Prince A. Pseudomonas aeruginosa cell-to-cell signaling is required for virulence in a model of acute pulmonary infection. Infect Immun 2000;68:4331-4.
64. Smith RS, Harris SG, Phipps R, Iglewski B. The Pseudomonas aeruginosa quorum-sensing molecule N-(3-oxododecanoyl) homoserine lactone contributes to virulence and induces inflammation in vivo. J Bacteriol 2002;184:1132-9.
65. Wu H, Song Z, Givskov M, Doring G, Worlitzsch D, Mathee K, et al. Pseudomonas aeruginosa mutations in lasI and rhlI quorum sensing systems result in milder chronic lung infection. Microbiology 2001;147:1105-13.
66. Singh PK, Schaefer, AL, Parsek, MR, Moninger, TO, Welsh, MJ, Greenberg, EP. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 2000;407:762-4.
67. Parsek MR, Greenberg EP. Quorum sensing signals in development of Pseudomonas aeruginosa biofilms. Methods Enzymol 1999;310:43-55.
68. Parsek MR, Greenberg EP. Acyl-homoserine lactone quorum sensing in gram-negative bacteria: a signaling mechanism involved in associations with higher organisms. Proc Natl Acad Sci USA 2000;97:8789-93.
69. De Kievit TR, Iglewski BH. Quorum sensing, gene expression, and Pseudomonas biofilms. Methods Enzymol 1999;310:117-28.
70. Sauer K, Camper AK, Ehrlich GD, Costerton JW, Davies DG. Pseudomonas aeruginosa displays multiple phenotypes during development as a biofilm. J Bacteriol 2002;184:1140-54.
71. Storey DG, Ujack EE, Rabin HR, Mitchell I. Pseudomonas aeruginosa lasR transcription correlates with the transcription of lasA, lasB, and toxA in chronic lung infections associated with cystic fibrosis. Infect Immun 1998;66:2521-8.
72. Erickson DL, Endersby R, Kirkham A, Stuber K, Vollman DD, Rabin HR, et al. Pseudomonas aeruginosa quorum-sensing systems may control virulence factor expression in the lungs of patients with cystic fibrosis. Infect Immun 2002;70:1783-90.
73. Charlton TS, de Nys R, Netting A, Kumar N, Hentzer M, Givskov M, et al. A novel and sensitive method for the quantification of N-3-oxoacyl homoserine lactones using gas chromatography-mass spectrometry: application to a model bacterial biofilm. Environ Microbiol 2000;2:530-41.
74. DiMango E, Zar HJ, Bryan R, Prince A. Diverse Pseudomonas aeruginosa gene products stimulate respiratory epithelial cells to produce interleukin-8. J Clin Invest 1995;96:2204-10.
75. Smith RS, Fedyk ER, Springer TA, Mukaida N, Iglewski BH, Phipps RP IL-8 production in human lung fibroblasts and epithelial cells activated by the Pseudomonas autoinducer N-3-oxododecanoyl homoserine lactone is transcriptionally regulated by NF-kappa B and activator protein-2. J Immunol 2001;167:366-74.
76. Telford G, Wheeler D, Williams P, Tomkins PT, Appleby P, Sewell H, et al. The Pseudomonas aeruginosa quorum-sensing signal molecule N-(3-oxododecanoyl)-L-homoserine lactone has immunomodulatory activity. Infect Immun 1998;66:36-42.
77. Chhabra SR, Harty C, Hooi DS, Daykin M, Williams P, Telford G, et al. Synthetic analogues of the bacterial signal (quorum sensing) molecule N-(3-oxododecanoyl)-L-homoserine lactone as immune modulators. J Med Chem 2003;46:97-104.
78. Tateda K, Ishii Y, Horikawa M, Matsumoto T, Miyairi S, Pechere JC, et al. The Pseudomonas aeruginosa autoinducer N-3-oxododecanoyl homoserine lactone accelerates apoptosis in macrophages and neutrophils. Infect Immun 2003;71:5785-93.
79. de Kievit TR, Iglewski BH Bacterial quorum sensing in pathogenic relationships. Infect Immun 2000;68:4839-49.
80. Miller MB, Bassler BL. Quorum sensing in bacteria. Annu Rev Microbiol 2001;55:165-99.
81. Whitehead NA, Barnard AM, Slater H, Simpson NJ, Salmond GP. Quorum-sensing in Gram-negative bacteria. FEMS Microbiol Rev 2001;25:365-404.
82. Schauder S, Bassler BL. The languages of bacteria. Genes Dev 2001;15:1468-80.
83. Reverchon S, Chantegrel B, Deshayes C, Doutheau A, Cotte-Pattat N. New synthetic analogues of N-acyl homoserine lactones as agonists or antagonists of transcriptional regulators involved in bacterial quorum sensing. Bioorg Med Chem Lett 2002;12:1153-7.
84. Smith KM, Bu Y, Suga H. Induction and inhibition of Pseudomonas aeruginosa quorum sensing by synthetic autoinducer analogs. Chem Biol 2003;10:81-9.
85. Hentzer M, Wu H, Andersen JB, Riedel K, Rasmussen TB, Bagge N, et al. Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J 2003;22:3803-15.
86. Tateda K, Comte R, Pechere JC, Kohler T, Yamaguchi K, Van Delden C. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2001;45:1930-3.
87. Nalca Y, Jansch L, Bredenbruch F, Geffers R, Buer J, Haussler S. Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach. Antimicrob Agents Chemother 2006;50:1680-8.